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Abstract
Amiloride is a potassium-sparing diuretic that has been used as an anti-kaliuretic for the chronic management of
hypertension and heart failure. Several studies have identified a potential anti-cancer role for amiloride, however the
mechanisms underlying its anti-tumor effects remain to be fully delineated. Our group previously demonstrated that
amiloride triggers caspase-independent cytotoxic cell death in human glioblastoma cell lines but not in primary astrocytes.
To delineate the cellular mechanisms underlying amiloride’s anti-cancer cytotoxicity, cell permeant and cell impermeant
derivatives of amiloride were synthesized that exhibit markedly different potencies in cancer cell death assays. Here we
compare the cytotoxicities of 5-benzylglycinyl amiloride (UCD38B) and its free acid 5-glycinyl amiloride (UCD74A) toward
human breast cancer cells. UCD74A exhibits poor cell permeability and has very little cytotoxic activity, while UCD38B is cell
permeant and induces the caspase-independent death of proliferating and non-proliferating breast cancer cells. UCD38B
treatment of human breast cancer cells promotes autophagy reflected in LC3 conversion, and induces the dramatic swelling
of the endoplasmic reticulum, however these events do not appear to be the cause of cell death. Surprisingly, UCD38B but
not UCD74A induces efficient AIF translocation from the mitochondria to the nucleus, and AIF function is necessary for the
efficient induction of cancer cell death. Our observations indicate that UCD38B induces programmed necrosis through AIF
translocation, and suggest that its cytosolic accessibility may facilitate drug action.
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Introduction
Most currently employed cancer therapeutics initiate apoptotic
death in actively proliferating cancer cells. While such agents
exhibit a significant degree of efficacy, two key barriers to more
effective cancer treatment remain. First, because therapeutic
regimens tend to target rapidly proliferating cells, any subset of
cells that are dormant or that proliferate slowly can evade
therapeutic intervention and give rise to either primary tumor
recurrence or the emergence of metastatic lesions [1]. Second,
tumor cells commonly activate potent anti-apoptotic pathways to
promote their survival and drug resistance [2]. Thus, the
development of small molecules that act independently of cell
cycle progression to engage non-apoptotic cell death mechanisms
offers a particularly attractive approach to thwart tumor progres-
sion [3].
Numerous studies in recent years point to the existence of
programmed cell death (PCD) mechanisms that are distinct from
caspase-dependent (type I) apoptosis [4–7]. For example, autoph-
agy, or type II PCD, is a stress-induced salvage pathway employed
by cells experiencing limited nutrients. Through this mechanism
cells sequester bulk cytoplasm and organelles into double
membrane vesicles, which ultimately fuse with lysosomes to
mediate the degradation of their contents and provide nutrients
to support cell survival [8,9]. However, if the stressful conditions
become overwhelming the type II PCD pathway can trigger
caspase-independent cell death.
Historically, necrosis has been conceptualized as a non-specific
cell death process, involving the disruption of the plasma
membrane and extrusion of the cytosolic contents, with the
potential induction of inflammatory response. However, very
recent studies indicate that some necrotic processes, such as
programmed necrosis (type III PCD), are under the control of the
cell and contribute to both physiological and pathological
processes [10,11]. While many of the molecular and cellular
details of programmed necrosis remain to be elucidated, it is now
recognized that programmed necrosis can be orchestrated by key
cellular factors such as the mitochondrial flavoprotein apoptosis-
inducing factor (AIF), and is characterized by the swelling of
organelles such as mitochondria and the endoplasmic reticulum
followed by the loss of plasma membrane integrity.
Amiloride, an FDA-approved diuretic that acts on epithelial
sodium channels, has been demonstrated in numerous studies to
suppress the growth and metastasis of a variety of tumor types in
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rat and mouse models (reviewed in [12]). We have demonstrated
that high-dose amiloride treatment is cytotoxic toward cultured
glioma cell lines but does not affect primary rat astrocytes at the
same concentration, and that cytotoxicity is caspase-independent
and independent of amiloride’s inhibitory activities toward the
type 1 sodium-proton exchanger (NHE1) and the sodium-calcium
exchanger (NCX) [13,14]. Moreover, the amiloride derivatives 5-
(N-ethyl-N-isopropyl)-amiloride (EIPA) and hexamethylene amil-
oride (HMA) have been reported to reduce the growth, viability,
motility and invasiveness of hepatocellular carcinoma cells and
xenografts [15–17]. HMA has also been shown to induce cell
death in leukemic cells, while not affecting the viability of normal
hematopoietic cells [18]. Taken together, these observations
suggest that amiloride and its derivatives exhibit selective anti-
cancer cytotoxicity independent of its ion channel inhibitory
activity, making this class of drugs attractive for future clinical
evaluation.
A major challenge to repurposing amiloride as an anti-cancer
therapeutic is its low potency in cytotoxicity assays. In the present
study we have examined the breast cancer cell cytotoxicity of two
amiloride derivatives modified at the C(5) position with different
substituents. Surprisingly, we observed that the more potent of
these derivatives induces cell death via AIF-mediated programmed
necrosis, raising the possibility that such amiloride derivatives may
Figure 1. Differential cell permeability of amiloride derivatives. (A) The structures of amiloride and the two C(5) derivatives employed in
these studies are depicted. The Bn in the UCD38B structure refers to a benzyl group. (B) MDA-MB-231 cells were incubated with vehicle control or
250 mM amiloride, UCD74A or UCD38B for 10 minutes and rinsed with PBS. Treated cells were then imaged by brightfield (upper panels) or
fluorescence (lower panels) microscopy, the fluorescence intensities of 20 randomly selected cells were quantified, and averages with standard error
are indicated.
doi:10.1371/journal.pone.0063038.g001
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be employed to attack tumor cells inherently resistant to apoptosis-
inducing therapeutics. Moreover, its cytotoxic activity appears to
correlate with its cell permeability, suggesting the existence of a
novel intracellular target for amiloride and its derivatives.
Materials and Methods
Reagents and Chemicals
UCD74A and UCD38B were synthesized, purified and handled
as previously described [19]. Amiloride (Sigma, St. Louis, MO),
UCD74A, and UCD38B were dissolved in DMSO as 200 mM
stocks, cisplatin (Calbiochem) as a 20 mM stock, and ionomycin
(Calbiochem) as a 5 mM stock. Compounds were stored in the
dark at 220uC. The pancaspase inhibitor z-VAD-fmk (Biovision,
Mountain View, CA) was used at 1 mM concentration and
treatments were carried out for 24 hours. The Green Multi-
Caspase Staining kit was purchased from PromoKine and was
employed according to the manufacturer’s instructions. The
autophagy inhibitors chloroquine and compound C (Sigma) were
used at 10 mM and 25 mM, respectively, and treatment was
carried out for 24 hours.
Cell Culture
All cell lines were obtained from American Type Culture
Collection. MDA-MB-231 and MCF-7 cells were cultured in
Dulbecco’s modified Eagle’s medium, while SKBR3 cells were
cultured in McCoy’s 5A medium. Media contained 10% bovine
fetal calf serum and 2% v/v penicillin/streptomycin. Cells were
maintained at 37uC in a 10% CO2 humidified incubator.
Immunoblot Analysis
After treatment with inhibitors, cells were lysed in SDS sample
buffer, lysates were resolved by 12% SDS-polyacrylamide gel
electrophoresis, and proteins transferred to nitrocellulose. Mem-
branes were blocked for 1 hour with 5% milk in Tris-buffered
saline/0.05% Tween-20 (TBST) followed by overnight 4uC
incubation in primary antibodies. Blots were then washed with
TBST and incubated with HRP-conjugated secondary antibody
(goat anti-mouse or anti-rabbit IgG, Invitrogen-Molecular Probes)
Figure 2. Induction of breast tumor cell death by the amiloride
derivative UCD38B. (A) MDA-MB-231, (B) MCF7, and (C) SKBR3
breast cancer cells were exposed for 24 hours to various concentrations
of amiloride, UCD74A, or UCD38B, as indicated. Cell viability was
measured using the MTT assay. Results depicted in each panel are
representative of three independent experiments.
doi:10.1371/journal.pone.0063038.g002
Figure 3. UCD38B-induced cell death occurs independently of
the cell cycle and proliferation. MDA-MB-231 cells were left
untreated (None) or were treated with scrambled (Scr) or cyclin D1
knockdown (KD) siRNA oligonucleotides for 72 hours. (A) Lysates were
immunoblotted for cyclin D1 and actin proteins. (B) Cell proliferation
after 24 hours was measured by MTT assay. (C) Cells treated with either
scrambled control (squares) or knockdown (circles) oligonucleotides
were exposed to increasing concentrations of UCD38B for 24 hours, and
the fraction cell viability was determined using the MTT assay. Results
depicted in each panel are representative of at least three independent
experiments. *, P,0.05.
doi:10.1371/journal.pone.0063038.g003
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for one hour at room temperature. Visualization of chemilumi-
nescence signal was carried out using an Alpha Innotech Digital
Imaging Station. Primary antibodies employed include PARP-1,
cleaved caspase-7, LC3, GAPDH, CREB (Cell Signaling Tech-
nology, MA), actin (Sigma, St. Louis, MO), CyclinD1 (Thermo
Scientific, Fremont, CA) and Beclin1 H-300 and AIF B-9 (Santa
Cruz Biotechnology, CA).
Live Cell (MTT) Tetrazolium Assay
Cells were seeded in 24-well plates and grown overnight, and
then treated with various compounds for an additional 24 hours.
Cells were then treated with 0.5 mg/ml 3-(4,5-Dimethyl-thiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) for 2 hours at 37uC,
media was removed, and formazan crystals were dissolved with
300 ml of acidic isopropyl alcoholic solution. 200 ml of sample was
transferred to a 96-well plate, and absorbance was measured at
570 nm with 655 nm reference. The absolute optical density was
normalized to time-matched, vehicle-treated control cells and
expressed as percent viability.
Cytotoxic Lactate Dehydrogenase (LDH) Assay
Cells were seeded in 24-well plates and grown overnight. After
treatment with and without inhibitors, 100 ml of supernatant per
well was transferred into a 96-well plate and cellular LDH release
Figure 4. Amiloride and UCD38B do not induce breast tumor cell death through caspase-dependent apoptosis. MDA-MB-231 cells
were treated for 24 hours with various concentrations of (A,B) amiloride or (C,D) UCD38B. (A,C) Cell lysates were immunoblotted with antibodies to
PARP to assess cleaved PARP (arrow) formation, and with antibodies specific for cleaved caspase-7. CP indicates treatment with 50 mM cisplatin. (B,D)
The viability of MDA-MB-231 cells after 24 hours was measured by MTT after treatment with various concentrations of amiloride or UCD38B in the
presence and absence of 1 mM z-VAD-fmk. (E) Cells were treated without and with 50 mM CP for 24 hours in the presence of either DMSO control or
1 mM unlabled z-VAD-fmk to block caspase labeling. Cells were then treated with FITC-z-VAD-fmk, and stained cells determined and quantified by
fluorescence microscopy. (F) Cells were treated with 5 mM tamoxifen in the presence and absence of 1 mM z-VAD-fmk, as indicated, and cell viability
was measured using an MTT assay. Results depicted in each panel are representative of at least three independent experiments.
doi:10.1371/journal.pone.0063038.g004
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from injured cells was determined using the LDH Cytotoxicity
Detection Kit (Clontech) according to the manufacture’s instruc-
tions. Treated cells were normalized to time-matched positive
control cells treated with 1% Triton X-100 (Sigma, MO).
Fluorescence Microscopy
The three amiloride derivatives exhibit similar intrinsic fluores-
cence (unpublished observations), and their visualization was
carried out as previously described [20] using an Olympus BX61
deconvolving fluorescence microscope with excitation at 350 nm
and emission at 460 nm. For AIF localization studies, cells were
cultured in chamber slides overnight, and then treated with
DMSO or 250 mM UCD38B, UCD74A or amiloride for 2 hours
at 37uC. Cells were washed with PBS and fixed with 4%
paraformaldehyde at room temperature for 15 minutes, then
washed with PBS and permeabilized with 80% methanol in PBS
for 5 minutes. Cells were blocked with 3% non-fat dried milk/1%
BSA in PBS for 1 hour at room temperature and incubated with
1:100 anti-AIF mAb in 0.1% BSA/PBS overnight at 4uC. Alexa
Fluor 488-conjugated anti-mouse IgG (Invitrogen-Molecular
Probes, Eugene, OR) was used at 1:500 dilution in 0.1% BSA/
PBS for 1 hour at room temperature. After PBS wash, slides were
mounted with mounting media containing 49,6-diamidino-2-
phenylindole (DAPI; Invitrogen-Molecular Probes). Imaging was
carried out using a confocal microscope (Olympus).
Electron Microscopy
Cells were plated in 8-well chambered slides overnight and then
treated with 250 mMUCD38B, UCD74A or amiloride for 2 hours
at 37uC. Cells were fixed in Karnovsky fixative and were imaged
using a Philips 120 BioTwin electron microscope at 80 KV
equipped with a Gatan MegaScan model 794/20 digital camera.
Cellular Fractionation
After treatment with inhibitors, cells were trypsinized, spun at
3006g for 5 minutes, resuspended in hypotonic buffer (20 mM
Tris-HCl pH 7.4, 10 mM NaCl, 3 mM MgCl2), transferred to a
pre-chilled microcentrifuge tube and incubated on ice for 15
minutes. 25 ml 10% NP-40 was added and the tube was vortexed
for 10 seconds. The homogenate was centrifuged at 18006g at
4uC and both the supernatant (cytosolic fraction) and pellet
(nuclear fraction) were collected. The nuclear fraction was
resuspended in 50 ml extraction buffer (100 mM Tris/HCl,
pH 7.4, 2 mM Na3V04, 100 mM NaCl, 1% Triton X-100,
1 mM EDTA, 10% glycerol, 1 mM EGTA, 0.1% SDS, 1 mM
NaF, 0.5% deoxycholate, 20 mM Na4P2O7, 1 mM AEBSF, 4 mg/
ml pepstatin A, 4 mg/ml leupeptin, 4 mg/ml aprotinin) for 30
minutes on ice with vortexing for 5 second every 10 minutes. The
sample was then centrifuged for 30 minutes at 14,0006g at 4uC
and the supernatant (nuclear extract) was collected. Cytosolic and
nuclear samples were treated with SDS sample buffer and
immunoblotting analysis was performed as described above.
siRNA Knockdown
Cells were seeded in 24-well plates and were grown for 16
hours. Cells were then transfected with 100 nM ON-TARGET-
plus SMARTpool RNAi oligonucleotides (Dharmacon) directed to
AIF, cyclinD1, or beclin1, or with nontargeting siRNA per
manufacturer’s instructions. Proliferation assays and immunoblot-
ting were carried out after 48 hours as described above.
FACS Assessment of Necrosis
MDA-MB-231 cells were treated with DMSO, 250 mM
UCD38B, or 50 mM cisplatin (CP) for 24 hours, and suspended
cells were incubated with FITC-Annexin V and propidium iodide
(PI) from BD Pharmingen FITC Annexin V Apoptosis Detection
Kit 1 as described by the manufacturer. Cells were sorted using a
Becton Dickinson FACScan flow cytometer, data were collected
using Cell Quest version 3.3 software and analyzed using FloJo
version 7.6.5 software.
Statistical Analysis
Values are expressed as mean 6 standard error and were
calculated from experiments carried out in triplicate. P values were
determined using the independent two sample t-test with values
less than 0.05 considered statistically significant (*, P,0.05; **,
P,0.001).
Figure 5. UCD38 does not significantly increase Annexin V staining. MDA-MB-231 cells were treated as indicated with DMSO control, 50 mM
cisplatin (CP) as an inducer of caspase-mediated apoptosis, or 250 mM UCD38B, and then analyzed by FACS for annexin V binding and propidium
iodide uptake. The accumulation of cells in quadrant (Q2) is characteristic of apoptosis while the accumulation of cells in quadrant 1 (Q1) is
characteristic of necrosis.
doi:10.1371/journal.pone.0063038.g005
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Results
Cytotoxicity of Amiloride Derivatives Correlates with Cell
Permeability
To begin to develop amiloride derivatives that exhibit greater
potency in tumor cell death assays, we have replaced the C(5)-
amino group with glycine to make compound UCD74A, or
additionally added benzyl alcohol to the glycine carboxylate to
make the more hydrophobic compound UCD38B [20] (see
Figure 1A). Surprisingly, we observed that the cytotoxic potencies
of these compounds correlate with their cell permeabilities. Using
the intrinsic fluorescence of all three compounds to assess their
cellular uptake by fluorescence microscopy (Figure 1B), we
observed that amiloride modestly accumulates within MDA-MB-
231 breast tumor cells, UCD38B is far more permeant, while
UCD74A appears to be largely excluded from the cell interior.
These observations indicate that modification of the 5-amino
group of amiloride can markedly alter the cell permeability of
analogs.
To assess the impact of the derivatives on tumor cell viability,
we first examined a panel of cultured human breast cancer cell
lines using the MTT assay. Breast cancer is a general descriptor
applied to several genetically and pathologically distinct diseases
that may be distinguished using the biomarkers HER2, estrogen
receptor (ER), and progesterone receptor (PR), and strategies for
treatment can vary markedly depending on classification. SKBR3
cells are a model of HER2-positive breast cancer, MCF7 cells are
a model of ER/PR-positive breast cancer, and MDA-MB-231
cells are a model of triple-negative or basal breast cancer. While
we observed some variability among the model cell lines, each line
was sensitive to amiloride (Figure 2) at concentrations previously
observed to kill cultured human glioma cells [13,14], suggesting
Figure 6. UCD38B does not cause cell death via autophagy. (A,B) MDA-MB-231 cells were treated for 24 hours with increasing concentrations
of UCD38B in the presence of DMSO control, 10 mM Compound C, or 25 mM chloroquine (CQ). (A) Lysates were immunoblotted for LC3 and actin, and
(B) viability was determined using the MTT cell death assay. (C,D) Cells were transfected with scrambled control or Beclin1-directed siRNA
oligonucleotides, and (C) lysates were immunoblotted for beclin1, LC3 and actin, and (D) viability was determined using the MTT cell death assay.
doi:10.1371/journal.pone.0063038.g006
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that the drug may act broadly toward multiple tumor types and
subtypes. We observed that amiloride exhibits a modest potency
toward each of the cell lines, eliciting half-maximal effects at 100–
200 mM and full effects at .500 mM. UCD38B is more than twice
as potent as amiloride in all cell lines, while UCD74A is relatively
inert (Figure 2). These observations indicate that the cytotoxic
potency of amiloride can be modulated by modification of its C(5)
position. Moreover, the results illustrated in Figures 1B and 2
strongly suggest that cell permeability may play a significant role in
the cytotoxicity of the drug.
UCD38B-induced Cell Death Occurs Independently of the
Cell Cycle
The majority of anti-cancer chemotherapeutics target cycling
cells, limiting their efficacy toward dormant cells that could re-
initiate primary breast tumors or seed metastatic lesions. To
determine whether UCD38B cytotoxic effects are cell cycle-
dependent, we examined the impact of cyclin D1 knockdown on
UCD38B-induced cytotoxicity. Since amiloride and its derivatives
exhibited qualitatively similar effects on all three breast cancer cell
lines, subsequent cell death studies were limited to the highly
malignant MDA-MB-231 line. siRNA-mediated cyclin D1 knock-
down suppresses cyclin D1 protein levels in MDA-MB-231 cells by
greater than 95% (Figure 3A), decreases the fraction of cells in S-
phase from 14% to 5% (not shown), and suppresses proliferation
as measured by MTT assay by greater than 50% (Figure 3B).
However, impeding cell cycle progression at G1/S has no
discernable effect on the ability of UCD38B to induce cell death
(Figure 3C), indicating that proliferation is not a requirement for
the cytotoxicity of this class of drugs.
Apoptosis and Autophagy do not Account for UCD38B
Cytotoxicity
To elucidate the mechanism of UCD38B-induced cell death, we
first asked whether amiloride or UCD38B induce canonical
caspase-dependent apoptosis. Consistent with our previous obser-
vations that amiloride promotes the caspase-independent death of
cultured human glioblastoma cells [13,14], we observed that
amiloride does not induce PARP and caspase-7 cleavage in MDA-
MB-231 breast tumor cells, and that co-incubation with the
caspase inhibitor z-VAD-fmk does not significantly attenuate the
cytotoxicity of amiloride (Figures 4A and 4B). Likewise, UCD38B
induces only modest PARP and caspase-7 cleavage compared to
the apoptosis-inducing agent cisplatin, and its cytotoxic potency is
unaffected by z-VAD-fmk (Figure 4C and 4D). Under these
conditions, z-VAD-fmk efficiently binds to caspases within cells
(Figure 4E) and inhibits tamoxifen-induced MDA-MB-231 cells
(Figure 4F) as previously described [21]. In addition, treatment of
cells with UCD38B does not significantly promote staining of cells
with FITC-Annexin V, a marker of apoptosis, but efficiently
induces the uptake of propidium iodide, a marker of cell
permeability and death (Figure 5). Taken together, these
Figure 7. UCD38B treatment results in rapid swelling of the endoplasmic reticulum. MDA-MB-231 cells were treated with (A) DMSO
control (x11357), (B) amiloride (x15455), (C) UCD74A (x15455) or (D–F) UCD38B (x15455, x20500, x38518) for two hours, and fixed cells were imaged
by transmission electron microscopy. Examples of endoplasmic reticulum (ER) and mitochondrial (M) structures are indicated.
doi:10.1371/journal.pone.0063038.g007
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observations indicate that even though UCD38B very modestly
induces PARP and caspase-7 cleavage, it acts through a cell death
pathway that is largely independent of canonical apoptosis.
Autophagy is a homeostatic cellular process that attempts to
preserve cell viability under environmental stress, but can initiate
cell death if conditions become too harsh [22]. UCD38B induces
an autophagic response in MDA-MB-231 cells, as reflected in the
elevation of the autophagy protein LC3 and its lipid modification
to the LC3-II form (Figure 6A). However, inhibition of the
autophagic process by the AMPK inhibitor compound C or the
lysosomotropic agent chloroquine [23,24] (Figures 6A and 6B), or
by a greater than 90% knockdown of the autophagy protein
beclin-1 (Figures 6C and 6D), does not disrupt UCD38B-induced
cell death. Taken together, these observations indicate that
autophagic cell death likely does not account for UCD38B anti-
cancer cytotoxicity.
UCD38B does not Induce Necrotic Cell Death through
Calcium-mediated Calpain Activation
We have observed that UCD38B but not UCD74A triggers the
formation of large intracellular vacuoles, membranous structures
derived from intracellular organelles that are frequently formed in
response to cell stress [6]. To determine whether UCD38B-
induced cytotoxicity might involve structural changes to specific
intracellular organelles, we carried out transmission electron
micrographic analysis of MDA-MB-231 cells treated with DMSO
control or with UCD74A or UCD38B for two hours. We observed
that UCD38B (Figures 7D–F) but not UCD74A (Figure 7C)
induces the massive dilation of the endoplasmic reticulum (ER) by
one to two orders of magnitude, resulting in the formation of large
cytosolic vacuoles in essentially every treated cell. Amiloride
treatment induces similar changes as UCD38B (Figure 7B), except
that morphological differences are far less pronounced. These
observations indicate that the disruption of ER integrity is
associated with UCD38B cytotoxicity.
We have recently demonstrated that cytosolic free calcium levels
are elevated in glioblastoma cells relative to primary astrocytes,
and that further calcium elevation induces cell death [14]. These
observations raise the possibility that the observed structural
alterations in the ER could trigger an increase in cytoplasmic free
calcium, leading to calpain activation the induction of necrosis.
This mechanism has been implicated in the dehydroeburicoic
acid-induced necrotic death of glioblastoma cells [25]. To
determine whether calcium-dependent necrosis contributes to
UCD38B-dependent cytotoxicity, we examined cell death using
the lactate dehydrogenase (LDH) release assay, a measurement of
the extrusion of cytosolic contents from necrotic cells. We observed
that UCD38B does indeed provoke the release of LDH from dying
cells (Figure 8A), indicating that the compound likely induces a
necrotic mechanism of cell death. However, pre-treatment of cells
with the calcium chelator BAPTA-AM did not affect UCD38B-
induced cell death under conditions where it inhibited ionomycin-
induced cell death (Figure 8A). Moreover, treatment of cells with
RIP1 inhibitor necrostatin-1 [26] did not affect cell death
(Figures 8B) under conditions where it inhibits necroptic cell
death by shikonin ([27] Figure 8C). Together, these observations
strongly suggest that UCD38B induces a form of necrosis distinct
from that mediated by calcium-induced calpain and RIP1-
mediated necroptosis.
UCD38B Induces AIF Nuclear Translocation
Since it has been previously suggested that AIF translocation
from mitochondria to the nucleus initiates caspase-independent
necrosis [28], we examined the localization of AIF without and
with amiloride, UCD74A or UCD38B treatment by cellular
fractionation (Figures 9A and 9B), and by confocal immunoflu-
orescence microscopy (Figure 9C). Both assays revealed a
significant translocation of AIF from the cytosol, presumably the
mitochondria, to the nucleus specifically upon treatment with
cytotoxic concentrations of 38B.
To determine whether AIF contributes to cytotoxicity, we
examined the impact of AIF knockdown on UCD38B-induced cell
death. siRNA-mediated AIF knockdown led to 65–75% suppres-
sion of the protein over a course of 2–5 days (Figures 10A and
10B), and led to a reproducible reversal of UCD38B cytotoxicity
Figure 8. UCD38B does not induce calcium-dependent necro-
sis. (A) LDH cell death assays were carried out with MDA-MB-231 cells
that were treated with UCD38B and ionomycin (IM) for 24 hours with
and without 1 hour pre-treatment with 10 mM BAPTA-AM. (B) Cell
viability after 24 hours was measured in the absence and presence of
25 mM RIP1 necroptosis inhibitor necrostatin-1 using the MTT assay. (C)
LDH cell death assays were carried out with cells treated with 8 mM
shikonin or 250 mM UCD38B in the presence and absence of 25 mM
necrostatin-1. Results depicted in each panel are representative of three
independent experiments. *, P,0.05; **, P,0.001.
doi:10.1371/journal.pone.0063038.g008
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toward MDA-MB-231 cells (Figure 10C). While the incomplete
reversal of UCD38B-induced cell death is likely the result of
incomplete AIF knockdown, these observations indicate that AIF
contributes substantially to UCD38B cytotoxicity.
Discussion
The current study builds upon our previous observations that
amiloride selectively induces the caspase-independent death of
glioma cells relative to non-transformed glial cells [13,14]. Here
we extend our analysis to examine the impact of two amiloride
derivatives on breast cancer cell lines, allowing us to draw several
key conclusions concerning the suitability of amiloride derivatives
in attacking malignant tumors.
Our comparison of amiloride-based congeners UCD38B and
UCD74A demonstrate that the modification of the C(5) amino
group of the amiloride parent compound can significantly impact
its cytotoxic activity; modification with the 5-benzylglycinyl moiety
potentiates cytotoxicity while conversion of the C(5) amino group
to glycine inhibits this function. These observations suggest that
bulkier or more hydrophobic substituents at this position may
augment cytotoxicity. Our future studies will be directed toward
further augmenting the cytotoxic potential of amiloride by
evaluating the potency of other C(5) derivatives.
Surprisingly, we observed that although UCD38B induces an
autophagic response, its mechanism of cytotoxicity is via AIF-
dependent programmed necrosis or type III PCD. While necrotic
cell death has traditionally been conceptualized as a non-specific
process, a series of recent studies has revealed that necrosis can be
divided into different subtypes, some of which are regulated and
may be exploited for therapeutic benefit [29]. Many of the
morphological and biochemical characteristics of these subtypes
are reflected in UCD38B-treated breast cancer cells, however,
none of the previously described programmed necrosis mecha-
nisms account for all of the changes that we observe in breast
tumor cells after UCD38B treatment.
Parthanatos and necroptosis are recently described forms of
type III PCD that are characterized by AIF translocation, but they
differ in the mechanisms underlying flavoprotein release from the
mitochondria. In parthanatos PARP processing promotes the
formation of PAR polymers, which translocate to the mitochon-
dria from the nucleus to promote AIF release [30]. AIF release in
necroptosis is triggered by various stimuli including calpains,
Figure 9. AIF translocates to the nucleus upon treatment of cells with UCD38B. (A) MDA-MB-231 cells were treated with 500 mM amiloride,
or 250 mM UCD38B for 2 hours, and cells were fractionated into nuclear (N) and cytosolic (C) components. Fractions were immunoblotted for CREB
and histone H3 as nuclear markers, GAPDH as a cytosolic marker, and AIF. (B) Bands from the blot depicted in (A) were digitally quantified, and the
nuclear AIF as a fraction of the total AIF was plotted for each condition. (C) Cells were treated for 2 hours with DMSO control or 250 mM amiloride,
UCD74A or UCD38B. Cells were then fixed and stained with DAPI to visualize the nucleus (blue) and antibodies to AIF (green), and examined by
confocal fluorescence microscopy. Results depicted in each panel are representative of 2–3 independent experiments.
doi:10.1371/journal.pone.0063038.g009
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cathepsins, reactive oxygen species, and Bax, and is dependent on
the RIP1 kinase [29,31]. However, our observations that 38B-
induced cell death is not affected by PARP or calpain inhibitors
(not shown), or the RIP1 inhibitor necrostatin-1 (Figures 8B and
8C), rule out these two mechanisms.
Paraptosis is a type III PCD that is characterized by extensive
vacuolation and swelling of the endoplasmic reticulum and
mitochondria, and caspase-independent cell death [8]. Methuosis,
another type III PCD, is also characterized by the presence of
large cytosolic vacuoles that are formed through macropinocytosis
by clathrin-independent endocytic vesicle trafficking [32]. In
contrast, amiloride has been demonstrated to inhibit macropino-
cytosis through its inhibition of NHE1 [33]. Like UCD38B, both
paraptosis and methuosis can produce an autophagic response that
is not required for cell death, however a role of AIF in these cell
death processes has not been described [34,35]. Thus, the precise
mechanism of UCD38B-induced programmed necrosis remains to
be delineated.
A key question that emerges from our studies concerns the
molecular target of UCD38B action. The anti-cancer effects of
amiloride have been ascribed to its inhibition of sodium-hydrogen
exchanger (NHE1) and urokinase plasminogen activator (uPA)
[12], however, our previous studies have ruled out NHE1. While
uPA remains a possibility, our observations point to a strong
correlation between cytotoxic potency of the amiloride derivatives
and their cell permeability. Thus, either UCD38B acts on an
intracellular uPA form that harbors protease activity and is
essential for tumor cell viability, or an unknown intracellular target
Figure 10. AIF is required for efficient UCD38B-induced cell death. (A) MDA-MB-231 cells were left untreated, or were treated with
scrambled control (scr) or AIF-directed (KD) siRNA oligonucleotides for the indicated number of days. Cell lysates were immunoblotted for actin and
AIF. (B) The blots from (A) were quantified and the relative amount of AIF (AIF/actin ratio) plotted. (C) Cells were treated with control or knockdown
oligonucleotides for 3 days, then treated without or with 500 mM amiloride, 250 mM UCD74A or 250 mM UCD38B for another 24 hours, and the
percent of cells that exhibit trypan blue uptake was evaluated. Results depicted in each panel are representative of three independent experiments.
**, P,0.001.
doi:10.1371/journal.pone.0063038.g010
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remains to be identified. Our current studies are directed toward
resolving these possibilities.
In summary, our studies provide the impetus for the develop-
ment of new amiloride-based anti-cancer small molecules that
initiate cell cycle-independent type III cell death in cancer cells. As
these agents act on cells independent of their proliferative state, we
predict that they would act synergistically with radiation therapy
and conventional chemotherapies that target proliferating cancer
cells. Moreover, slowly proliferating or dormant cancer cells could
be effectively targeted by this class of compounds. Finally, cancer
cells that are resistant to apoptosis-inducing drugs, including
tumor-initiating or cancer stem cells, may also be targeted by this
class of necrosis-inducing agents.
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